GUIDE-seq™ Intellectual Property Licensing
Non-Exclusive Intellectual Property License
Organizations using GUIDE-seq as part of their product characterization strategy may require access to GUIDE-seq intellectual property.
MaxCyte offers non-exclusive GUIDE-seq licenses for organizations developing CRISPR-based gene-editing therapeutics.
If your organization is currently using GUIDE-seq technology, we welcome the opportunity to discuss a non-exclusive license solution for your therapeutic development program.
Licensing at a Glance
Why Consider a GUIDE-seq License?
As gene-editing programs advance through development, organizations using GUIDE-seq as part of their product characterization strategy may require access to GUIDE-seq intellectual property.
MaxCyte works collaboratively with therapeutic developers to evaluate appropriate non-exclusive license solutions that support the continued advancement of gene-editing programs.
Beyond Licensing
One partner for GUIDE-seq intellectual property licensing and analytical characterization services.
MaxCyte's SeQure™ portfolio provides comprehensive genome editing characterization solutions to support therapeutic development.
- GUIDE-seq assay services
- On-target editing characterization
- Off-target editing assessment
- Genotoxicity risk assessment
- Regulatory-supporting analytical services
Contact Us
Complete the form to learn more about our GUIDE-seq licensing and the full scope of MaxCyte's SeQure™ portfolio.
